SPRB
Spruce Biosciences Inc
$
0.079
- Overview
- Forecast
- Valuation
High
0.1049
Open
0.095
VWAP
0.09
Vol
13.15M
Mkt Cap
21.90M
Low
0.0779
Amount
1.19M
EV/EBITDA(TTM)
--
Total Shares
41.15M
EV
-21.50M
EV/OCF(TTM)
--
P/S(TTM)
0.95
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigating tildacerfont for the treatment of classic CAH in children.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
0.00
-100%
-0.070
-87.72%
0.00
-100%
-0.150
-28.57%
125.00K
-93.76%
-0.150
-31.82%
Estimates Revision
The market is revising No Change the revenue expectations for Spruce Biosciences, Inc. (SPRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -80.74%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-80.74%
In Past 3 Month
4 Analyst Rating
536.13% Upside
Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 0.50 USD with a low forecast of 0.50 USD and a high forecast of 0.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
4 Hold
0 Sell
Hold
536.13% Upside
Current: 0.079
Low
0.50
Averages
0.50
High
0.50
536.13% Upside
Current: 0.079
Low
0.50
Averages
0.50
High
0.50
RBC Capital
Gregory Renza
Hold
Maintains
$1.5 → $0.5
2025-04-16
Reason
RBC Capital
Gregory Renza
Price Target
$1.5 → $0.5
2025-04-16
Maintains
Hold
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Reiterates
n/a
2024-12-16
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
n/a
2024-12-16
Reiterates
Hold
Reason
Guggenheim
Evan Wang
Hold
Reiterates
n/a
2024-12-12
Reason
Guggenheim
Evan Wang
Price Target
n/a
2024-12-12
Reiterates
Hold
Reason
Oppenheimer
Hartaj Singh
Buy
to
Hold
Downgrades
n/a
2024-12-11
Reason
Oppenheimer
Hartaj Singh
Price Target
n/a
2024-12-11
Downgrades
Buy
to
Hold
Reason
Oppenheimer downgraded Spruce Biosciences to Perform from Outperform without a price target. The company announced disappointing topline results from both of its ongoing trials of tildacerfont, the analyst tells investors in a research note. The firm awaits clarity on next steps with Spruce winding down both trials and prioritizing cash conservation as it evaluates strategic alternatives.
RBC Capital
Gregory Renza
Hold
Reiterates
$2 → $1.5
2024-12-11
Reason
RBC Capital
Gregory Renza
Price Target
$2 → $1.5
2024-12-11
Reiterates
Hold
Reason
JMP Securities
Jonathan Wolleben
Buy
to
Hold
Downgrades
$3
2024-12-11
Reason
JMP Securities
Jonathan Wolleben
Price Target
$3
2024-12-11
Downgrades
Buy
to
Hold
Reason
JMP Securities downgraded Spruce Biosciences to Market Perform from Outperform without a price target. The firm is stepping to the sidelines after tildacerfont missed in the Phase 2b CAHmelia-204 trial. Despite some evidence of more effective twice-daily doses in the Phase 2 CAHptain-205 trial, the data apparently are not convincing enough for further investment in congenital adrenal hyperplasia, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Spruce Biosciences Inc (SPRB.O) is -0.17, compared to its 5-year average forward P/E of -2.38. For a more detailed relative valuation and DCF analysis to assess Spruce Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.38
Current PE
-0.17
Overvalued PE
0.47
Undervalued PE
-5.22
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.17
Current EV/EBITDA
0.33
Overvalued EV/EBITDA
2.25
Undervalued EV/EBITDA
-4.59
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
-67.34
Current PS
0.00
Overvalued PS
242.45
Undervalued PS
-377.13
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+14.72%
-14.49M
Operating Profit
FY2025Q1
YoY :
+20.78%
-14.04M
Net Income after Tax
FY2025Q1
YoY :
+14.29%
-0.32
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
281.9K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SPRB News & Events
Events Timeline
2025-04-15 (ET)
2025-04-15
07:07:16
Spruce acquires tralesinidase alfa enzyme replacement therapy
2024-11-11 (ET)
2024-11-11
07:05:24
Spruce Biosciences reports Q3 EPS (21c), consensus (24c)
2024-09-11 (ET)
2024-09-11
07:20:01
Competitor disappointments bode well for Neurocrine, says BofA
Sign Up For More Events
Sign Up For More Events
News
4.5
04-28BenzingaCrude Oil Down 2%; Roper Technologies Increases 2025 Outlook
2.0
04-28BenzingaDow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
4.0
04-28BenzingaHC Wainwright & Co. Reiterates Neutral on Spruce Biosciencesto Neutral
Sign Up For More News
People Also Watch
META
Meta Platforms Inc
659.360
USD
+0.51%
AMZN
Amazon.com Inc
210.250
USD
-0.53%
NVDA
NVIDIA Corp
135.340
USD
+4.16%
XOM
Exxon Mobil Corp
108.480
USD
-0.90%
AVGO
Broadcom Inc
232.120
USD
-0.13%
ORCL
Oracle Corp
162.950
USD
+0.42%
WMT
Walmart Inc
96.830
USD
+0.99%
TSLA
Tesla Inc
347.680
USD
+4.07%
AAPL
Apple Inc
212.330
USD
-0.28%
MSFT
Microsoft Corp
452.940
USD
+0.85%
FAQ
What is Spruce Biosciences Inc (SPRB) stock price today?
The current price of SPRB is 0.0786 USD — it has decreased -39.29 % in the last trading day.
What is Spruce Biosciences Inc (SPRB)'s business?
What is the price predicton of SPRB Stock?
What is Spruce Biosciences Inc (SPRB)'s revenue for the last quarter?
What is Spruce Biosciences Inc (SPRB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Spruce Biosciences Inc (SPRB)'s fundamentals?
How many employees does Spruce Biosciences Inc (SPRB). have?